Design of DNA damaging agents that hijack transcription factors and block DNA repair

Advances in Experimental Medicine and Biology

Volumn 500, Issue , 2001, Pages 301-313

  Essigmann, John M ^a   Rink, Stacia M ^a   Park, Hyun Ju ^a   Croy, Robert G ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 PHENYLINDOLE DERIVATIVE; ANILINE MUSTARD; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CISPLATIN; DNA; ESTROGEN RECEPTOR; TRANSCRIPTION FACTOR;

ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CONFERENCE PAPER; DNA ADDUCT; DNA DAMAGE; DNA REPAIR; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG MECHANISM; DRUG SYNTHESIS; GENOTOXICITY; HUMAN; PRIORITY JOURNAL;

EID: 0035697686     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-0667-6_47     Document Type: Conference Paper

References (48)

1. Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin
2. Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin
3. Biological processing of DNA modified by platinum compounds
4. Ultraviolet light-induced sister chromatid exchanges in xeroderma pigmentosum and in Cockayne's syndrome lymphocyte cell lines
5. An unnatural biopolymer
6. Cellular responses to cisplatin
7. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling
8. Uracil-DNA glycosylase as a probe for protein-DNA interactions
9. Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin
10. Human MutSalpha recognizes damaged DNA base pairs containing O6- methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct
11. The steroid and thyroid hormone receptor superfamily
12. Estrogen and progesterone receptor analyses in more than 4000 human breast cancer samples
13. A novel role for DNA photolyase: Binding to DNA dmamged by drugs is associated with enhanced toxicity in Saccharomyces cerevisiae
14. Isolation and partial characterization of human cell mutants differing in sensitivity to killing and mutation by methylnitrosourea and N-methyl-N′-nitro-N-nitrosoguanidine
15. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease
16. Influence of cell proliferation and cell cycle phase on expression of estrogen receptor in MCF-7 breast cancer cells
17. Cisplatin inhibits synthesis of ribosomal RNA in vivo
18. Tamoxifen and tumorigenicity: A predictable concern
19. 6-methylguanine residues in E. coli DNA
20. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
21. Antiestrogen resistance: Mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy
22. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells
23. Relation between estrogen inhibitory activity and binding to cytosol of rabbit and human uterus
24. Estrogen receptor-binding affinity and cytotoxic activity of three new estrogen-nitrosourea conjugates in human breast cancer cell lines in vitro
25. Carcinogenesis by alkylating agents
26. Guide-lines in the design of new antiestrogens and cytotoxic-linked estrogens for the treatment of breast cancer
27. Development of antiestrogens and their use in breast cancer: Eighth cain memorial award lecture
28. Cisplatin
29. Interaction of human immunodeficiency virus type 1 tat-derived peptides with TAR RNA
30. Sensitivity of testis tumour cells to chemotherapeutic drugs: Role of detoxifying pathways
31. The HMG-domain protein Ixr1 blocks excision repair of cisplatin-DNA adducts in yeast
32. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin
33. Cloning of a yeast 8-oxoguanine DNA glycosylase reveals the existence of a base-excision DNA-repair protein superfamily
34. Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen
35. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin
36. Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies
37. Synthesis and biological activity of DNA damaging agents that form decoy binding sites for the estrogen receptor
38. Synthesis of novel androgen-linked phosporamide mustard prodrugs and growth-inhibitory activity in human breast cancer cells
39. Role of poly(ADP-ribose) formation in DNA repair
40. Isolation of cDNAs encoding a human protein that binds selectively to DNA modified by the anticancer drug cisdiamminedichloroplatinum(II)
41. The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties
42. Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor)
43. Cisplatin- and UV-damaged DNA lure the basal transcription factor TFIID/TBP
44. 2-Phenylindoles. Relationship between structure, estrogen receptor affinity and mammary tumor inhibiting activity in the rat
45. Multiple pathways of recombination define cellular responses to cisplatin
46. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor
47. CDK-Independent activation of estrogen receptor by cyclin D1